2024
Association of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substances
Havlik J, Rhee T, Rosenheck R. Association of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substances. PLOS ONE 2024, 19: e0302544. PMID: 38683850, PMCID: PMC11057773, DOI: 10.1371/journal.pone.0302544.Peer-Reviewed Original ResearchConceptsIllicit substance use disordersCannabis use disorderSubstance use disordersMental health-related quality of lifeUse disorderTreatment usePast-year CUDRates of treatment usePast-year substance use disorderMental health-related qualityMental health related qualityBehavioral health factorsLegal statusNegative associationNESARC-IIISUD treatment useMultiple regression analysisDisordersHealth-related quality of lifeIllegal substancesHealth related qualityUnadjusted analysisQuality of lifeAUDDiagnostic factors
2023
Association of Recent and Past Suicide Attempts With Health-Related Quality of Life.
Bommersbach T, Rosenheck R, Rhee T. Association of Recent and Past Suicide Attempts With Health-Related Quality of Life. The Journal Of Clinical Psychiatry 2023, 84 PMID: 36856537, DOI: 10.4088/jcp.22m14441.Peer-Reviewed Original ResearchConceptsMental component scorePhysical component scoreSuicide prevention initiativesSuicide attemptsOverall health-related qualityMajor public health priorityPrevention initiativesHealth-related qualitySubstance use comorbiditiesMeasures of HRQOLRelated Conditions Wave IIILower MCS scoresMultivariable regression analysisPublic health prioritySubstance use disordersComponent scoresNational Epidemiologic SurveyQuality of lifeRecent suicide attemptAssociation of suicidePast suicide attemptsPrior attemptsMCS scoresUnadjusted analysesHealth priority
2022
Beyond Supported Housing: Correlates of Improvements in Quality of Life Among Homeless Adults with Mental Illness
O’Connell M, Tsai J, Rosenheck R. Beyond Supported Housing: Correlates of Improvements in Quality of Life Among Homeless Adults with Mental Illness. Psychiatric Quarterly 2022, 94: 49-59. PMID: 36538200, DOI: 10.1007/s11126-022-10010-x.Peer-Reviewed Original ResearchRacial and ethnic differences in suicidal behavior and mental health service use among US adults, 2009–2020
Bommersbach T, Rosenheck R, Rhee T. Racial and ethnic differences in suicidal behavior and mental health service use among US adults, 2009–2020. Psychological Medicine 2022, 53: 5592-5602. PMID: 36106374, PMCID: PMC10482716, DOI: 10.1017/s003329172200280x.Peer-Reviewed Original ResearchConceptsPast-year suicidal ideationMental health service useHealth service useService useSuicidal ideationSuicide attemptsRace/ethnicityHispanic individualsWhite individualsEthnic differencesSuicidal behaviorSuicidal thoughts/behaviorsMental health servicesThoughts/behaviorsSI/SAMultivariable adjustmentUS adultsUS civilianDrug useHealth servicesProportion of whitesPast-year suicide attemptsHealthcare systemNational surveySuicide rates
2013
Incarceration Histories of Homeless Veterans and Progression Through a National Supported Housing Program
Tejani N, Rosenheck R, Tsai J, Kasprow W, McGuire J. Incarceration Histories of Homeless Veterans and Progression Through a National Supported Housing Program. Community Mental Health Journal 2013, 50: 514-519. PMID: 23728839, DOI: 10.1007/s10597-013-9611-9.Peer-Reviewed Original Research
2012
Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study
Zhang X, Chen D, Xiu M, Haile C, He S, Luo X, Zuo L, Rosenheck R, Kosten T, Kosten T. Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study. Psychological Medicine 2012, 43: 1651-1660. PMID: 23149169, DOI: 10.1017/s0033291712002590.Peer-Reviewed Original ResearchConceptsDrug-naive patientsFES patientsGeneral populationCognitive functionChronic schizophreniaHealthy controlsSmoking ratesFirst-episode drug-naive patientsFirst-episode schizophrenia patientsQuantity of smokingPositive symptom subscale scoresCase-control studyHigh smoking ratesSymptom subscale scoresCase-control designNegative Symptom ScaleTotal PANSSCigarette smokingFirst episodeNicotine dependenceFagerström TestPatientsPsychotic disordersSmokingSymptom Scale
2007
Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. JAMA Psychiatry 2007, 64: 1259-1268. PMID: 17984395, DOI: 10.1001/archpsyc.64.11.1259.Peer-Reviewed Original ResearchConceptsCost-benefit analysisSecond-generation antipsychoticsGreatest net health benefitNet benefit analysisNet health benefitWholesale priceHealth Utilities Index Mark 3Economic perspectiveAlzheimer's diseaseBenefit approachHealth care costsTotal health costsHealth costsQALYsCare costsMeasures of effectivenessPlacebo-controlled trialLower health care costsHealth service useTotal health careMeasures of functionCostTreatment of psychosisQuality of lifeSensitivity analysisFactors Associated With Stigma Among Caregivers of Patients With Bipolar Disorder in the STEP-BD Study
Gonzalez J, Perlick D, Miklowitz D, Kaczynski R, Hernandez M, Rosenheck R, Culver J, Ostacher M, Bowden C. Factors Associated With Stigma Among Caregivers of Patients With Bipolar Disorder in the STEP-BD Study. Psychiatric Services 2007, 58: 41-48. PMID: 17215411, DOI: 10.1176/ps.2007.58.1.41.Peer-Reviewed Original ResearchConceptsMental illness stigmaCaregivers of patientsIllness stigmaFactors associated with stigmaCaregivers of personsCaregivers of peopleMeasures of stigmaCross-sectional designUnwell groupPatient's illness stateAssociated with bipolar IBipolar disorderCaregiver stigmaStepwise multiple regressionAssociated with factorsMeasures of diagnosisSocial supportCaregiversStigmaEpisode statusPhase of illnessSystematic Treatment Enhancement ProgramCollege educationSTEP-BD studyAdult children
2006
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment OutcomeSpecial Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
Chakos M, Glick I, Miller A, Hamner M, Miller D, Patel J, Tapp A, Keefe R, Rosenheck R. Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial. Psychiatric Services 2006, 57: 1094-1101. PMID: 16870959, DOI: 10.1176/ps.2006.57.8.1094.Peer-Reviewed Original ResearchConceptsConcomitant psychotropic medicationsPsychotropic medicationsConcomitant medication useIntervention Effectiveness (CATIE) trialOnly partial responseSecond-generation antipsychoticsBetter neurocognitive functioningClinical Antipsychotic TrialsPartial responseCATIE trialMedication useAnticholinergic drugsBaseline useMedication dataMood stabilizersCases symptomsConcomitant useEffectiveness trialAntipsychotic TrialsMedicationsNeurocognitive functioningSchizophreniaBaseline dataTrialsAntipsychoticsSpecial Section on CATIE Baseline Data: Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia
Chwastiak L, Rosenheck R, McEvoy J, Keefe R, Swartz M, Lieberman J. Special Section on CATIE Baseline Data: Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia. Psychiatric Services 2006, 57: 1102-1109. PMID: 16870960, DOI: 10.1176/ps.2006.57.8.1102.Peer-Reviewed Original ResearchConceptsMedical comorbiditiesMedical conditionsPsychiatric symptom severityPsychosocial functioningNeurocognitive impairmentSchizophrenia symptomsBaseline dataSymptom severityCross-sectional studyPhysical health statusSample of patientsClinical Antipsychotic TrialsPoorer neurocognitive functioningGreater depressive symptomsSevere schizophrenia symptomsSample of personsDiabetes mellitusAntipsychotic pharmacotherapyIndependent associationAntipsychotic TrialsMultivariate regression modelComorbiditiesPsychotic symptomsDepressive symptomsHealth statusSpecial Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia
Perlick D, Rosenheck R, Kaczynski R, Swartz M, Cañive J, Lieberman J. Special Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia. Psychiatric Services 2006, 57: 1117-1125. PMID: 16870962, DOI: 10.1176/ps.2006.57.8.1117.Peer-Reviewed Original ResearchConceptsMedication side effectsQuality of lifeDaily livingService useSide effectsAcute inpatient phaseImpact of symptomsPatient problem behaviorsClinical Antipsychotic TrialsPatient's symptomsCaregiver burdenInpatient phaseAntipsychotic TrialsFamily burdenFamily caregiversCaregiver dataPatient behaviorTreatment programPatients' impairmentIncorporation of skillsSymptomsIntervention effectivenessDemographic characteristicsPrevious monthSchizophrenia
2003
Cost-effectiveness of Supported Housing for Homeless Persons With Mental Illness
Rosenheck R, Kasprow W, Frisman L, Liu-Mares W. Cost-effectiveness of Supported Housing for Homeless Persons With Mental Illness. JAMA Psychiatry 2003, 60: 940-951. PMID: 12963676, DOI: 10.1001/archpsyc.60.9.940.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase ManagementCommunity-Institutional RelationsCost of IllnessCost-Benefit AnalysisFemaleFinancing, GovernmentGovernment AgenciesHealth Care CostsHealth StatusHumansIll-Housed PersonsMaleMental DisordersProgram EvaluationProspective StudiesPublic HousingSocial AdjustmentSubstance-Related DisordersUnited StatesUnited States Department of Veterans AffairsVeteransConceptsStandard care groupIntensive case managementStandard careCase managementCare groupMore daysMental illnessVeterans AffairsIncremental cost-effectiveness ratioSuperior housing outcomesSubstance abuse statusHUD-VASHMental health statusSubstance abuse disordersCost-effectiveness ratioCommunity adjustmentMental illness resultsSupported housing programsSecondary outcomesPrimary outcomeAbuse disordersIllness resultsControl groupHealth statusSocietal perspective
2001
Time-Limited Assertive Community Treatment for Homeless Persons With Severe Mental Illness
Rosenheck RA, Dennis D. Time-Limited Assertive Community Treatment for Homeless Persons With Severe Mental Illness. JAMA Psychiatry 2001, 58: 1073-1080. PMID: 11695955, DOI: 10.1001/archpsyc.58.11.1073.Peer-Reviewed Original ResearchConceptsSevere mental illnessMental illnessService useHealth statusOutpatient health service useSubstance abuseAssertive community treatment modelHealth service useAssertive community treatmentMental health statusRandom-effects modelCommunity treatment modelHospital daysPublic support paymentsCommunity treatmentCommunity careIllnessMental healthMore daysMonthsTreatment modelHomeless personsEffects modelAnnual cohortsHomeless clientsImpact of Clozapine Prescription on Inpatient Resource Utilization
SERNYAK M, ROSENHECK R, DESAI R, STOLAR M, RIPPER G. Impact of Clozapine Prescription on Inpatient Resource Utilization. The Journal Of Nervous And Mental Disease 2001, 189: 766-773. PMID: 11758660, DOI: 10.1097/00005053-200111000-00006.Peer-Reviewed Original ResearchConceptsInpatient resource utilizationClozapine treatmentInpatient daysComparison groupService utilization variablesMore inpatient daysClozapine prescriptionIndex dischargeRefractory schizophreniaConventional neurolepticsTypical neurolepticsClinical variablesVA databasesInpatient hospitalizationInpatient careYear treatmentUtilization variablesClozapineTreatmentNeurolepticsPatientsSchizophreniaUsing a computerized patient database to evaluate guideline adherence and measure patterns of care for major depression
Rosenheck R, Chen R. Using a computerized patient database to evaluate guideline adherence and measure patterns of care for major depression. The Journal Of Behavioral Health Services & Research 2001, 28: 466-474. PMID: 11732248, DOI: 10.1007/bf02287776.Peer-Reviewed Original ResearchConceptsPatterns of careMajor depressionGuideline adherenceGuideline recommendationsOutpatient mental health appointmentsVeterans Affairs Medical CenterComputerized database analysisMental health appointmentsMonths of dischargeComputerized patient databaseNumber of followTranslation of recommendationsHealth care policyAntidepressant therapyHealth appointmentsMedical CenterAlcohol abuseDual diagnosisTreatment interventionsPatient databaseComputerized databasePatientsConcurrent alcoholismDatabase analysisDepressionThe proportion of veterans among homeless men: a decade later
Gamache G, Rosenheck R, Tessler R. The proportion of veterans among homeless men: a decade later. Social Psychiatry And Psychiatric Epidemiology 2001, 36: 481-485. PMID: 11768845, DOI: 10.1007/s001270170012.Peer-Reviewed Original ResearchMental and Physical Health and Acculturation among Hispanic Vietnam Veterans
Ortega A, Rosenheck R. Mental and Physical Health and Acculturation among Hispanic Vietnam Veterans. Military Medicine 2001, 166: 894-897. PMID: 11603242, DOI: 10.1093/milmed/166.10.894.Peer-Reviewed Original ResearchConceptsPhysical health risksHispanic Vietnam veteransHispanic veteransPhysical healthVietnam veteransNon-Hispanic whitesHealth risksOutcome measuresSecondary data analysisAcculturation indexEpidemiological studiesHealth outcomesMental healthVeteransMexican AmericansHealthAcculturation scoresRepresentative samplePredictive validityHispanicsPuerto RicansScoresRiskVietnam eraAssociationNeuroleptic Use in the Treatment of Post-Traumatic Stress Disorder
Sernyak M, Kosten T, Fontana A, Rosenheck R. Neuroleptic Use in the Treatment of Post-Traumatic Stress Disorder. Psychiatric Quarterly 2001, 72: 197-213. PMID: 11467155, DOI: 10.1023/a:1010318414199.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderTreatment of PTSDNeuroleptic useOutcome studiesStress disorderSevere post-traumatic stress disorderLarge outcome studiesUse of neurolepticsNeuroleptic-treated patientsObservational outcome studyCombat-related post-traumatic stress disorderIll patientsMedication historyClinical variablesNeuroleptic prescriptionSocio-demographic characteristicsTreatment characteristicsBaseline differencesNeurolepticsPatientsSecondary analysisPTSD symptomsCombat exposureTreatmentOutpatientsUse of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System
Leslie D, Rosenheck R. Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System. Medical Care 2001, 39: 923-933. PMID: 11502950, DOI: 10.1097/00005650-200109000-00003.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdultAntipsychotic AgentsComorbidityDelivery of Health Care, IntegratedDiagnosis, Dual (Psychiatry)FemaleGuideline AdherenceHumansMaleMental Health ServicesMiddle AgedNational Health ProgramsOutcome and Process Assessment, Health CarePatient CompliancePolypharmacyPractice Guidelines as TopicSchizophreniaUnited StatesUnited States Department of Veterans AffairsConceptsPatient Outcomes Research TeamLarger mental health systemMultiple antipsychotic medicationsAntipsychotic medicationPORT recommendationsSchizophrenia Patient Outcomes Research TeamVeterans AffairsHealth systemTotal weekly doseTreatment of schizophreniaPrescription drug recordsMental health systemHealth care systemGeneralized estimation equationsMultiple antipsychoticsNational Health SystemOlder patientsWeekly doseNational health care systemPharmacy dataComorbid depressionTreatment recommendationsDrug recordsMedicationsPatients